We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The law firm Cohen, Milstein, Hausfeld & Toll, P.L.L.C. has filed a lawsuit in the United States District Court for the District of New Jersey on behalf of its client and on behalf of other similarly situated purchasers of Par Pharmaceutical Companies, Inc. ("Par" or the "Company") between April 29, 2004 and July 5, 2006, inclusive (the "Class Period").
Two new targeted therapies for bowel cancer should not be used on Britain's state-run health service, the country's cost-effectiveness watchdog NICE said on Monday.
Oscient Pharmaceuticals has completed its acquisition of the U.S. rights to the cardiovascular product ANTARA 130 mg (fenofibrate) capsules from Reliant Pharmaceuticals.
Pharmaceuticals maker Wyeth, still resolving legal claims over a deadly diet drug, now faces lawsuits alleging that its menopause treatments can cause breast cancer.
The World Health Organization urged influenza vaccine makers to use newer strains of virus when making vaccine to protect against H5N1 avian flu, saying the evolution of the microbe has led to increased variety in circulating strains.
By 2010, generics will dominate the schizophrenia drug market, and Pfizer will be the only major drug firm to maintain a strong position after its current leading antipsychotic goes generic, according to an Aug. 11 report by research firm Datamonitor.
The FDA is partnering with the Massachusetts Institute of Technology (MIT) to develop new databases as part of a broad agency initiative to improve its postapproval monitoring of drugs, a high-ranking FDA official said.